SCN9A

(redirected from Nav1.7)
Also found in: Wikipedia.

SCN9A

A gene on chromosome 2q24 that encodes an alpha subunit of the voltage-gated sodium channel, which mediates voltage-dependent sodium ion permeability of excitable membranes. The SCN9A protein product plays a major role in nociception signalling.

Molecular pathology
SCN9A mutations are associated with primary erythromelalgia, channelopathy-associated insensitivity to pain and paroxysmal extreme pain disorder.
References in periodicals archive ?
The aim of the partnership is to accelerate Purdue's Nav1.
Nine VGSC subtypes are known to be expressed in different cell types, and among them subtype Nav1.
Chronic lithium treatment up-regulates cell surface NaV1.
This was later confirmed by tests showing bi-allelic mutations in the gene that codes for the voltage-gated sodium channel Nav1.
Using their novel approach venoms from 206 species of spider were screened revealing that 40% of the venoms contained at least one compound that blocked human Nav1.
The scientists said that voltage- sensitive sodium channels control the flow of sodium ions through the neuron's membrane and theses channels open and close by responding to the electric current or action potential of the cells, and that one particular type of sodium channel, called the Nav1.
Studies of rare inherited pain syndromes have pinpointed pivotal molecules that drive pain signaling by identifying, for the first time, a single gene or gene product, the Nav1.
They also revealed that patients with pain disorders such as erythromelalgia, small fiber neuropathy, and paroxysmal extreme pain disorder, contain mutant forms of Nav1.
Thought leaders we interviewed are enthusiastic regarding the clinical potential of these agents, in particular those targeting Nav1.
M2 EQUITYBITES-October 26, 2015-Genentech's second Nav1.
M2 PHARMA-October 26, 2015-Genentech's second Nav1.